

SAS:sas 11/05/02 151326  
PATENT

Attorney Reference Number 5673-59226  
Application Number 09/878,136

3. (Reiterated) A method according to claim 1, wherein the antigen-presenting cells consist essentially of dendritic cells.

4. (Reiterated) A method according to claim 1, wherein the cell-damaging agent consists essentially of a virus vector for gene delivery.

5. (Reiterated) A method according to claim 4, wherein the vector comprises one or more gene sequences encoding an immunomodulatory protein and/or a tumour antigen, or a functional fragment thereof.

6. (Reiterated) A method according to claim 1, wherein the cell-damaging agent and the antigen-presenting cells are delivered to target cells in vivo

7. (Reiterated) A method according to claim 1, wherein the cell-damaging agent and the antigen-presenting cells are delivered to target cells in vitro and the treated target cells are then implanted into a subject.

8. (Reiterated) A method of treating cell proliferation in a subject which comprises administering to said subject separately or concurrently a cell-damaging agent and a preparation of antigen presenting cells in combination with a pharmaceutical excipient.

**Please add the following new claims:**

--9. (New) The method according to claim 1, wherein the cell-damaging agent is a herpesvirus encoding GM-CSF.

B1 10. (New) The method according to claim 8, wherein the cell-damaging agent is a herpesvirus encoding GM-CSF.

11. (New) The method of claim 4, wherein the viral vector is a herpesvirus vector.